drugset / Trial / NCT00229697

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

NCT00229697

Phase 2 Completed 317 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.

Timeline

Start
2003-10
Primary completion
2006-12
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule 250 mg
Background Tamoxifen Small molecule 20 mg

Indications